Researchers at UMDNJ-New Jersey Dental
School in Newark are seeking women between the ages of 18 and 65 who suffer
from facial pain (TMJ) or temporomandibular disorders (TMD). The purpose
of the study is to determine the causes of facial pain and the appropriate
treatment. Volunteers must never have used oral appliances or bite plates
for treatment. Participants are required to complete daily questionnaires
at home for two weeks before undergoing a free six-week treatment program.
They will receive compensation of $300 upon completion of the study.
Women between 18 and 65 years of age without
facial pain are also needed for this research project. They will be asked
to complete daily questionnaires at home for two weeks and will be paid
$100 when the study is completed.
The project is directed by Karen Raphael, PhD,
and Joseph Marbach, DDS. For further information call the project coordinator,
Margaret Spier, at 973-972-8043.
Spinal Cord Injuries are Sought for Sexual Response Study
Kessler Institute for Rehabilitation
in West Orange was awarded a three-year grant from the NIH to conduct
a study of the physiologic effects of sexual functioning in spinal cord
injured individuals and to test new methods to improve sexual satisfaction.
Thirty women, particularly those with incomplete injuries, or with a spinal
cord injury at or below the level of T6, are being sought to participate.
Those who complete the study will receive compensation for travel expenses
and an honorarium of $500.
For more information call research assistant
Marie Dziekan, MA, at 800-248-3221, ext. 2711. The principal investigator
for this study is Marca L. Sipski, MD.
at Kessler Institute
Kessler Medical Rehabilitation Research
and Education Corporation in West Orange is conducting a study evaluating
the efficacy of oral Sildenafil (Viagra TM) in
the improvement of sexual responsiveness in women with spinal cord injuries
(SCI). Participants, particularly those with incomplete injuries, must
be premenopausal and between the ages of 18 and 55. Pregnant women are
not eligible to participate. Those who complete the study will receive
an honorarium of $200.
For further information regarding the study,
call research associate Marie Dziekan, MA, at 800-248-3221, ext. 2711.
The principal investigator for this study is Marca L. Sipski, MD.
at The Cancer Institute of New Jersey (CINJ) in New Brunswick develop
and conduct clinical trials for oncology patients who do not respond to
traditional therapies and for those with cancers that do not have a standard
treatment. The focus of these studies is to develop new treatment options
and drugs, as well as preventive and diagnostic techniques to fight the
disease. CINJ is the only cancer center in the state of New Jersey designated
by the National Cancer Institute (NCI) and one of 13 NCI-clinical cancer
centers in the country. CINJ offers advanced comprehensive care and its
research base has the potential to transform laboratory results into clinical
applications that reduce cancer incidence, morbidity and mortality.
The Cancer Institute
of New Jersey is currently conducting more than 60 clinical trials for
different types and stages of cancer. For additional information on specific
cancer clinical trials at CINJ, call the Clinical Research Office at 732-235-8666.
Raloxifene to Prevent Breast Cancer
The Cancer Institute of New Jersey
(CINJ) and UMDNJ-Robert Wood Johnson Medical School in New Brunswick have
been selected to participate in the National Surgical Adjuvant Breast
and Bowel Project's (NSABP) Study of Tamoxifen and Raloxifene (STAR).
STAR is the second major nationwide breast cancer prevention trial conducted
by the NSABP. The new study will examine whether raloxifene, a drug similar
to tamoxifen, is equally effective in preventing breast cancer and if
it offers any additional benefits than those obtained by tamoxifen. STAR
is a double-blind study designed to include postmenopausal women age 35
and older who are at increased risk for developing breast cancer. The
principal investigator for this study is Deborah Toppmeyer, MD. CINJ will
begin enrolling eligible participants in 1999. To be placed on a mailing
list to receive trial-related information or to schedule an appointment
to determine eligibility, call the Clinical Research Office at 732-235-8666.
Women Needed to Compare Standard Hormonal Therapy with Soy
Healthy postmenopausal women between
the ages of 40 and 66 are needed to participate in a study comparing standard
hormonal therapy (i.e. estrogen) with soy, in the form of oral pills,
at St. Peter's Medical Center in New Brunswick. The purpose of the study
is to evaluate the effects of soy on lipids, uterine lining, vagina, mood
and memory. To be eligible to participate, volunteers must be without
spontaneous menses for more than one year, must have a uterus and have
had a normal Pap smear and mammography within the past year. Participants
will receive $50 upon completion of the study.
This study is under the direction of Judi Chervenak,
MD. Contact Yu-Ling Lai, RN, at 732-745-6683 for additional information.
Volunteers with high blood cholesterol
are being sought to participate in a study at UMDNJ-Robert Wood Johnson
Medical School in New Brunswick. Participants must be between the ages
of 21 and 70. The purpose of the investigational study is to evaluate
the effectiveness of Zocor and Lipitor, drugs known to lower blood cholesterol
and decrease the risk of heart attacks. Those eligible will receive a
physical exam, study medications and laboratory tests at no charge.
This study is under the direction of the principal
investigator, Avedis K. Khachadurian, MD. Call Shelley Greenhaus, RN,
at 732-235-7751 for more information.
UMDNJ-Robert Wood Johnson Medical
School in New Brunswick is looking for women between the ages of 14 and
49 with at least moderate facial acne to participate in a six-month treatment
study of a marketed medication. Ten visits are necessary to complete the
study. Those eligible will receive a physical examination, Pap smear and
blood tests at no cost. After completion of the study, participants will
receive a monetary compensation of $90.
The investigators of this study are Gloria Bachmann,
MD, Gary Ebert, MD, and Amy Pappert, MD. Call 732-235-7353 or 732-235-7925,
Monday through Friday between 9 AM and 5 PM.
and Somatization Treatment Studies
The Department of Psychiatry at UMDNJ-Robert
Wood Johnson Medical School in Piscataway is conducting treatment studies
on depression and somatization. The depression study is seeking individuals
who are experiencing persistent depressed moods or loss of interest. Eligible
individuals will receive 16 free psychotherapy sessions - one per week
- during the study. Its purpose is to assess how effectively the therapy
reduces feelings of depression.
Individuals with multiple unexplained physical
symptoms may be eligible to participate in the somatization treatment
study. It involves 10 weekly sessions of a cognitive behavior therapy
that teaches patients methods for reducing their discomfort and coping
with their symptoms. Participants will be evaluated before treatment,
after it is completed and again six and 12 months later.
Michael Gara, PhD, is the study investigator
for the Depression Treatment Study and the Somatization Treatment Study
is under the direction of Lesley A. Allen, PhD.
For more information on both studies, contact
Lesley A. Allen at 732-235-4412.
The Clinical Research Center at UMDNJ-Robert
Wood Johnson Medical School in New Brunswick is seeking volunteers with
psoriasis to participate in research studies being conducted at the school.
Eligible participants will receive physical examinations by board-certified
dermatologists, laboratory tests and medication at no cost. Some programs
have monetary compensation.
The studies are under the direction of Alice
B. Gottlieb, MD, PhD. For further details and to find out if you qualify,
call study coordinator Amelia Sherr, RN, at 732-418-8474.
for High Blood Pressure and Diabetic Kidney Disease
Hypertension specialists at UMDNJ-Robert
Wood Johnson Medical School in New Brunswick are conducting a three-year
study to evaluate the effect of a new investigational medication for diabetic
kidney disease for individuals with Type II adult onset diabetes. To be
eligible, the participants must be between the ages of 30 and 70, have
Type II diabetes, high blood pressure and protein in their urine. The
purpose of the study is to determine the investigational medication's
ability to reduce the rate of progression of renal disease and other problems
associated with diabetic nephropathy.
The second study is to compare the ability of
an investigational medication to reduce the amount of protein in the urine
with a medication currently on the market to treat high blood pressure.
The study is for 16 weeks and those eligible must be 18 or older with
hypertension and Type II diabetes.
For both studies, participants will receive
study medications, physical exams, blood pressure monitoring and laboratory
tests, EKGs and chest x-rays at no cost. Monetary compensation is available
to those who complete the studies.
Both studies are under the direction of the
principal investigator, Michael C. Ruddy, MD. For more information on
both studies, call Noreen Bradley, RN, at 732-235-7825.
Volunteers age 18 and older with high
blood pressure are being sought to participate in a study. It will evaluate
the effectiveness of a new investigational medication and its effect on
hypertension in individuals with increases in blood pressure due to increases
in salt. The study is being conducted at UMDNJ-Robert Wood Johnson Medical
School by the Section of Hypertension in New Brunswick. It is approximately
eight weeks long and requires some overnight visits in the Clinical Research
Center. Participants who complete the study will receive monetary compensation
up to $1,200.
A 12-month study is also being conducted at
the school. The purpose of the study is to determine the safety and effectiveness
of a new investigational medication for those who have primary hypertension.
Participants will receive study medication, physical exams, blood pressure
monitoring and laboratory tests at no cost.
Michael C. Ruddy, MD, is the principal investigator
for the Hypertension Study and the 12-month study is under the direction
of Grace B. Bialy, MD. For additional information on both studies, call
Noreen Bradley, RN, at 737-235-7825.